UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
(Registrant’s telephone number, including area code)
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol | Name of each exchange on which registered | ||
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (§230.405 of this chapter) or Rule 12b-2 of the Exchange Act (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On July 16, 2024, Qualigen Therapeutics, Inc. (the “Company”) attended a hearing before the Nasdaq Hearings Panel (the “Panel”)regarding the Company’s potential delisting from The Nasdaq Stock Market due to non-compliance with the bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”) and the shareholder equity requirement pursuant to Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) or any of the alternative requirements pursuant to Nasdaq Listing Rule 5550(b). On August 2, 2024, the Company received the Panel decision which granted the Company until October 31, 2024 to regain compliance with the Bid Price Rule and the Equity Rule. If the Company is unable to regain compliance with the listing standards of the Nasdaq Capital Market by October 31, 2024, the Company’s securities may be delisted from The Nasdaq Stock Market.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
QUALIGEN THERAPEUTICS, INC. | ||
Date: August 5, 2024 | By: | /s/ Michael S. Poirier |
Michael S. Poirier, Chief Executive Officer |
Cover |
Aug. 02, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Aug. 02, 2024 |
Entity File Number | 001-37428 |
Entity Registrant Name | Qualigen Therapeutics, Inc. |
Entity Central Index Key | 0001460702 |
Entity Tax Identification Number | 26-3474527 |
Entity Incorporation, State or Country Code | DE |
Entity Address, Address Line One | 5857 Owens Avenue |
Entity Address, Address Line Two | Suite 300 |
Entity Address, City or Town | Carlsbad |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 92008 |
City Area Code | (760) |
Local Phone Number | 452-8111 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $.001 per share |
Trading Symbol | QLGN |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
-8?2
M0$3;8T.P6BP^0"X99K>]9!:G
E9]($*JHB1ZFWTE?#,;9$#
MQJF*^C*=#(D(SQP<"_% -)/X'ZH6'QR,2
M\M&,